This pivotal trial demonstrates a significant improvement in PFS with ARX788 monotherapy compared with lapatinib plus capecitabine in patients with HER2-positive ABC who had previously been treated with trastuzumab and taxane and had progressed on one line of trastuzumab-based treatment. The gene discussed is ERBB2; the disease is aneurysmal bone cyst.